Athira Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATHA research report →
About the company
Athira Pharma, Inc. , a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier.
- CEO
- Mark J. Litton
- IPO
- 2020
- Employees
- 26
- HQ
- Bothell, WA, US
Price Chart
- Market Cap
- $26.62M
- P/E
- -0.29
- P/S
- 0.00
- P/B
- 0.75
- EV/EBITDA
- -0.02
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -381.01%
- ROIC
- -169.53%
- Revenue
- $0 · 0.00%
- Net Income
- $-105,609,000 · -8.94%
- EPS
- $-24.70 · 1.98%
- Op Income
- $-102,266,000
- FCF YoY
- 52.96%
- 52W High
- $8.36
- 52W Low
- $2.20
- 50D MA
- $5.48
- 200D MA
- $4.03
- Beta
- 2.80
- Avg Volume
- 1.06M
Get TickerSpark's AI analysis on ATHA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 8, 21 | CHURCH KEVIN | other | 3,152 |
| May 18, 21 | CHURCH KEVIN | other | 185 |
| Jun 8, 21 | CHURCH KEVIN | other | 3,152 |
Our ATHA coverage
Recent articles, reports, and earnings notes.
No research on ATHA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATHA report →Similar companies
Peers in the same neighborhood.